Effect of chelators on the pharmacokinetics of 99mTc-labeled imaging agents for the prostate-specific membrane antigen (PSMA)

Journal of Medicinal Chemistry

Volumn 56, Issue 15, 2013, Pages 6108-6121

  Ray Banerjee, Sangeeta ^a   Pullambhatla, Mrudula ^a   Foss, Catherine A ^a   Falk, Alexander ^a   Byun, Youngjoo ^b   Nimmagadda, Sridhar ^a   Mease, Ronnie C ^a   Pomper, Martin G ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Korea University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CHELATING AGENT; PROSTATE SPECIFIC MEMBRANE ANTIGEN; TECHNETIUM 99M;

ALKYLATION; AMINATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLICK CHEMISTRY; CONTROLLED STUDY; DIASTEREOISOMER; DRUG BINDING; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG UPTAKE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; ISOTOPE LABELING; KIDNEY TUBULE ABSORPTION; LIPOPHILICITY; MALE; MOLECULAR IMAGING; MOUSE; NONHUMAN; PEPTIDE SYNTHESIS; PROSTATE CANCER; RADIOACTIVITY; RADIOCHEMISTRY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOLID PHASE EXTRACTION; TUMOR XENOGRAFT;

ANIMALS; ANTIGENS, SURFACE; CHELATING AGENTS; GLUTAMATE CARBOXYPEPTIDASE II; HYDRAZINES; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; MALE; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASM TRANSPLANTATION; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; STRUCTURE-ACTIVITY RELATIONSHIP; TECHNETIUM; TISSUE DISTRIBUTION; UREA;

EID: 84881429638     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm400823w     Document Type: Article

References (52)

1. Pillai, M. R. A.; Dash, A.; Knapp, F. F. Sustained Availability of 99mTc: Possible Paths Forward J. Nucl. Med. 2013, 54, 313-323
2. Alberto, R. Tc-99m Radiopharmaceuticals:Status and Trends; Radioisotopes and Radiopharmaceutical Series no. 1; International Atomic Energy Agency: Vienna, 2009.
3. Ghosh, A.; Heston, W. D. Tumor Target Prostate Specific Membrane Antigen (PSMA) and its Regulation in Prostate Cancer J. Cell Biochem. 2004, 91, 528-539
4. Akhtar, N. H.; Pail, O.; Saran, A.; Tyrell, L.; Tagawa, S. T. Prostate-Specific Membrane Antigen-Based Therapeutics Adv. Urol. 2012, 2012, 1-9
5. Chang, S. S.; Reuter, V. E.; Heston, W. D.; Gaudin, P. B. Comparison of Anti-Prostate-Specific Membrane Antigen Antibodies and Other Immunomarkers in Metastatic Prostate Carcinoma Urology 2001, 57, 1179-1183
6. Bander, N. H.; Milowsky, M. I.; Nanus, D. M.; Kostakoglu, L.; Vallabhajosula, S.; Goldsmith, S. J. Phase I Trial of 177Lutetium-Labeled J591, a Monoclonal Antibody to Prostate-Specific Membrane Antigen, in Patients with Androgen-Independent Prostate Cancer J. Clin. Oncol. 2005, 23, 4591-4601
7. Perner, S.; Hofer, M. D.; Kim, R.; Shah, R. B.; Li, H.; Moller, P.; Hautmann, R. E.; Gschwend, J. E.; Kuefer, R.; Rubin, M. A. Prostate-Specific Membrane Antigen Expression as a Predictor of Prostate Cancer Progression Hum. Pathol. 2007, 38, 696-701
8. Hillier, S. M.; Maresca, K. P.; Femia, F. J.; Marquis, J. C.; Foss, C. A.; Nguyen, N.; Zimmerman, C. N.; Barrett, J. A.; Eckelman, W. C.; Pomper, M. G.; Joyal, J. L.; Babich, J. W. Preclinical Evaluation of Novel Glutamate-Urea-Lysine Analogues that Target Prostate-Specific Membrane Antigen as Molecular Imaging Pharmaceuticals for Prostate Cancer Cancer Res. 2009, 69, 6932-6940
9. Foss, C. A.; Mease, R. C.; Cho, S. Y.; Kim, H. J.; Pomper, M. G. GCPII Imaging and Cancer Curr. Med. Chem. 2012, 19, 1346-1359
10. Cho, S. Y.; Gage, K. L.; Mease, R. C.; Senthamizhchelvan, S.; Holt, D. P.; Jeffrey-Kwanisai, A.; Endres, C. J.; Dannals, R. F.; Sgouros, G.; Lodge, M.; Eisenberger, M. A.; Rodriguez, R.; Carducci, M. A.; Rojas, C.; Slusher, B. S.; Kozikowski, A. P.; Pomper, M. G. Biodistribution, Tumor Detection, and Radiation Dosimetry of 18F-DCFBC, a Low-Molecular-Weight Inhibitor of Prostate-Specific Membrane Antigen, in Patients with Metastatic Prostate Cancer J. Nucl. Med. 2012, 53, 1883-1891
11. Barrett, J. A.; Coleman, R. E.; Goldsmith, S. J.; Vallabhajosula, S.; Petry, N. A.; Cho, S.; Armor, T.; Stubbs, J. B.; Maresca, K. P.; Stabin, M. G.; Joyal, J. L.; Eckelman, W. C.; Babich, J. W. First-in-Man Evaluation of 2 High-Affinity PSMA-Avid Small Molecules for Imaging Prostate Cancer J. Nucl. Med. 2013, 54, 380-387
12. Maresca, K. P.; Hillier, S. M.; Lu, G.; Marquis, J. C.; Zimmerman, C. N.; Eckelman, W. C.; Joyal, J. L.; Babich, J. W. Small Molecule Inhibitors of PSMA Incorporating Technetium-99m for Imaging Prostate Cancer: Effects of Chelate Design on Pharmacokinetics Inorg. Chim. Acta 2012, 389, 168-172
13. Nedrow-Byers, J. R.; Moore, A. L.; Ganguly, T.; Hopkins, M. R.; Fulton, M. D.; Benny, P. D.; Berkman, C. E. PSMA-Targeted SPECT Agents: Mode of Binding Effect on in Vitro Performance Prostate 2012, 73, 355-362
14. Lu, G.; Maresca, K. P.; Hillier, S. M.; Zimmerman, C. N.; Eckelman, W. C. J.; Babich, J. L. Synthesis and SAR of 99mTc/Re-Labeled Small Molecule Prostate Specific Membrane Antigen Inhibitors with Novel Polar Chelates Biorg. Med. Chem. Lett. 2013, 23, 1557-1563
15. Nedrow-Byers, J. R.; Jabbes, M.; Jewett, C.; Ganguly, T.; He, H.; Liu, T.; Benny, P.; Bryan, J. N.; Berkman, C. E. A Phosphoramidate-Based Prostate-Specific Membrane Antigen-Targeted SPECT Agent Prostate 2012, 72, 904-912
16. Banerjee, S. R.; Foss, C. A.; Castanares, M.; Mease, R. C.; Byun, Y.; Fox, J. J.; Hilton, J.; Lupold, S. E.; Kozikowski, A. P.; Pomper, M. G. Synthesis and Evaluation of Technetium-99m- and Rhenium-Labeled Inhibitors of the Prostate-Specific Membrane Antigen (PSMA) J. Med. Chem. 2008, 51, 4504-4517
17. Kularatne, S. A.; Zhou, Z.; Yang, J.; Post, C. B.; Low, P. S. Design, Synthesis, and Preclinical Evaluation of Prostate-Specific Membrane Antigen Targeted (99m)Tc-Radioimaging Agents Mol. Pharmaceutics 2009, 6, 790-800
18. Zhang, Y.; DiFilipp, F.; Doke, A.; Huang, J.; Heston, W.; Huang, S. Preliminary Micro-SPECT and Biodistribution Study of a Novel Tc99m-Labeled PSMA Tracer Derived from RBI1033 JNM Mtg. Abstr. 2012, 53 (Suppl 1) 1661
19. 3-labeled N (tau)-Histidine Folate Derivative with its Isostructural, Clicked 1,2,3-Triazole Analogue Bioconjugate Chem. 2008, 19, 1689-1695
20. Huisgen, R. 1,3-Dipolar Cycloadditions. Past and Future Angew. Chem., Int. Ed. 1963, 2, 565-598
21. Rostovtsev, V. V.; Green, L. G.; Fokin, V. V.; Sharpless, K. B. A Stepwise Huisgen Cycloaddition Process: Copper(I)-Catalyzed Regioselective "Ligation" of Azides and Terminal Alkynes Angew. Chem., Int. Ed. Engl. 2002, 41, 2596-2599
22. Banerjee, S. R.; Pullambhatla, M.; Byun, Y.; Nimmagadda, S.; Foss, C. A.; Green, G.; Fox, J. J.; Lupold, S. E.; Mease, R. C.; Pomper, M. G. Sequential SPECT and Optical Imaging of Experimental Models of Prostate Cancer with a Dual Modality Inhibitor of the Prostate-Specific Membrane Antigen Angew. Chem., Int. Ed. Engl. 2011, 50, 9167-9170
23. 2Br] Inorg. Chem. Commun. 2004, 7, 1023-1026
24. 2 Bifunctional Chelator for Technetium-99m and Rhenium: Complexation, Conjugation, and Epimerization to a Single Isomer Bioconjugate Chem. 1999, 10, 470-479
25. Banerjee, S. R.; Pullambhatla, M.; Byun, Y.; Nimmagadda, S.; Green, G.; Fox, J. J.; Horti, A.; Mease, R. C.; Pomper, M. G. Ga-68-Labeled Inhibitors of Prostate-Specific Membrane Antigen (PSMA) for Imaging Prostate Cancer J. Med. Chem. 2010, 53, 5333-5341
26. Wang, Y.; Liu, G.; Hnatowich, D. J. Methods for MAG3 Conjugation and 99mTc Radiolabeling of Biomolecules Nature Protoc. 2006, 1, 1477-1480
27. Greenland, W. E.; Howland, K.; Hardy, J.; Fogelman, I.; Blower, P. J. Solid-Phase Synthesis of Peptide Radiopharmaceuticals Using Fmoc- N -epsilon-(Hynic-Boc)-lysine, a Technetium-Binding Amino Acid: Application to Tc-99m-Labeled Salmon Calcitonin J. Med. Chem. 2003, 46, 1751-1757
28. Olszewski, R. T.; Bukhari, N.; Zhou, J.; Kozikowski, A. P.; Wroblewski, J. T.; Shamimi-Noori, S.; Wroblewska, B.; Bzdega, T.; Vicini, S.; Barton, F. B.; Neale, J. H. NAAG Peptidase Inhibition Reduces Locomotor Activity and Some Stereotypes in the PCP model of Schizophrenia via Group II mGluR J. Neurochem. 2004, 89, 876-885
29. Silver, D. A.; Pellicer, I.; Fair, W. R.; Heston, W. D.; Cordon-Cardo, C. Prostate-Specific Membrane Antigen Expression in Normal and Malignant Human Tissues Clin. Cancer Res. 1997, 3, 81-85
30. Jackson, P. F.; Cole, D. C.; Slusher, B. S.; Stetz, S. L.; Ross, L. E.; Donzanti, B. A.; Trainor, D. A. Design, Synthesis, and Biological Activity of a Potent Inhibitor of the Neuropeptidase N -Acetylated Alpha-Linked Acidic Dipeptidase J. Med. Chem. 1996, 39, 619-622
31. Bartholoma, M.; Valliant, J.; Maresca, K. P.; Babich, J.; Zubieta, J. Single Amino Acid Chelates (SAAC): A Strategy for the Design of Technetium and Rhenium Radiopharmaceuticals Chem. Commun. 2009, 493-512
32. Banerjee, S. R.; Maresca, K. P.; Francesconi, L.; Valliant, J.; Babich, J. W.; Zubieta, J. New Directions in the Coordination Chemistry of 99mTc: A Reflection on Technetium Core Structures and a Strategy for New Chelate Design Nucl. Med. Biol. 2005, 32, 1-20
33. Jurisson, S. S.; Lydon, J. D. Potential Technetium Small Molecule Radiopharmaceuticals Chem. Rev. 1999, 99, 2205-2218
34. Shi, J.; Kim, Y. S.; Chakraborty, S.; Jia, B.; Wang, F.; Liu, S. Mercaptoacetyl-glycylglycyl (MAG(2)) as a Bifunctional Chelator for (99m)Tc-Labeling of Cyclic RGD Dimers: Effect of Technetium Chelate on Tumor Uptake and Pharmacokinetics Bioconjugate Chem. 2009, 20, 1559-1568
35. Liu, S.; Edwards, D. S.; Looby, R. J.; Poirier, M. J.; Rajopadhye, M.; Bourque, J. P.; Carroll, T. R. Labeling Cyclic Glycoprotein IIb/IIIa Receptor Antagonists with 99mTc by the Preformed Chelate Approach: Effects of Chelators on Properties of [99mTc]Chelator-Peptide Conjugates Bioconjugate Chem. 1996, 7, 196-202
36. Rao, T. N.; Adhikesavalu, D.; Camerman, A.; Fritzberg, R. A. Technetium(V) and Rhenium(V) Complexes of 2,3-Bis(mercaptoacetamido)propanoate. Chelate Ring Stereochemistry and Influence on Chemical and Biological Properties J. Am. Chem. Soc. 1990, 112, 5798-5804
37. Leamon, C. P.; Parker, M. A.; Vlahov, I. R.; Xu, L. C.; Reddy, J. A.; Vetzel, M.; Douglas, N. Synthesis and Biological Evaluation of EC20: A New Folate-Derived, (99m)Tc-Based Radiopharmaceutical Bioconjugate Chem. 2002, 13, 1200-1210
38. Rovenska, M.; Hlouchova, K.; Sacha, P.; Mlcochova, P.; Horak, V.; Zamecnik, J.; Barinka, C.; Konvalinka, J. Tissue Expression and Enzymologic Characterization of Human Prostate Specific Membrane Antigen and its Rat and Pig Orthologs Prostate. 2008, 68, 171-182
39. Wallberg, H.; Orlova, A.; Altai, M.; Hosseinimehr, S. J.; Widstrom, C.; Malmberg, J.; Stahl, S.; Tolmachev, V. Molecular Design and Optimization of 99mTc-labeled Recombinant Affibody Molecules Improves Their Biodistribution and Imaging Properties J. Nucl. Med. 2011, 52, 461-469
40. Rusckowski, M.; Qu, T.; Gupta, S.; Ley, A.; Hnatowich, D. J. A Comparison in Monkeys of (99m)Tc Labeled to a Peptide by 4 Methods J. Nucl. Med. 2001, 42, 1870-1877
41. Decristoforo, C.; Mather, S. J. Technetium-99m somatostatin analogues: effect of labelling methods and peptide sequence Eur. J. Nucl. Med. 1999, 26, 869-76
42. Decristoforo, C.; Mather, S. J. Preparation, 99mTc-labeling, and in vitro characterization of HYNIC and N3S modified RC-160 and [Tyr3]octreotide Bioconjugate Chem. 1999, 10, 431-438
43. Chang, S. S.; Reuter, V. E.; Heston, W. D.; Bander, N. H.; Grauer, L. S.; Gaudin, P. B. Five Different Anti-Prostate-Specific Membrane Antigen (PSMA) Antibodies Confirm PSMA Expression in Tumor-Associated Neovasculature Cancer Res. 1999, 59, 3192-3198
44. Bzdega, T.; Crowe, S. L.; Ramadan, E. R.; Sciarretta, K. H.; Olszewski, R. T.; Ojeifo, O. A.; Rafalski, V. A.; Wroblewska, B.; Neale, J. H. The Cloning and Characterization of a Second Brain Enzyme with NAAG Peptidase Activity J. Neurochem. 2004, 89, 627-635
45. Hlouchova, K.; Barinka, C.; Klusak, V.; Sacha, P.; Mlcochova, P.; Majer, P.; Rulisek, L.; Konvalinka, J. Biochemical Characterization of Human Glutamate Carboxypeptidase III J. Neurochem. 2007, 101, 682-696
46. Pangalos, M. N.; Neefs, J. M.; Somers, M.; Verhasselt, P.; Bekkers, M.; van der Helm, L.; Fraiponts, E.; Ashton, D.; Gordon, R. D. Isolation and Expression of Novel Human Glutamate Carboxypeptidases with N -Acetylated Alpha-Linked Acidic Dipeptidase and Dipeptidyl Peptidase IV activity J. Biol. Chem. 1999, 274, 8470-8483
47. Hlouchova, K.; Barinka, C.; Konvalinka, J.; Lubkowski, J. Structural Insight into the Evolutionary and Pharmacologic Homology of Glutamate Carboxypeptidases II and III FEBS J. 2009, 276, 4448-4462
48. Eder, M.; Schafer, M.; Bauder-Wust, U.; Hull, W. E.; Wangler, C.; Mier, W.; Haberkorn, U.; Eisenhut, M. 68Ga-Complex Lipophilicity and the Targeting Property of a Urea-Based PSMA Inhibitor for PET Imaging Bioconjugate Chem. 2012, 23, 688-697
49. Afshar-Oromieh, A.; Malcher, A.; Eder, M.; Eisenhut, M.; Linhart, H. G.; Hadaschik, B. A.; Holland-Letz, T.; Giesel, F. L.; Kratochwil, C.; Haufe, S.; Haberkorn, U.; Zechmann, C. M. PET Imaging with a [(68)Ga]gallium-Labelled PSMA Ligand for the Diagnosis of Prostate Cancer: Biodistribution in Humans and First Evaluation of Tumour Lesions Eur. J. Nucl. Med. Mol. Imaging 2012, 40, 486-495
50. Kaiser, E.; Colescott, R. L.; Bossinger, C. D.; Cook, P. I. Color Test for Detection of Free Terminal Amino Groups in the Solid-Phase Synthesis of Peptides Anal. Biochem. 1970, 34, 595-598
51. Zhang, Y. M.; Liu, N.; Zhu, Z. H.; Rusckowski, M.; Hnatowich, D. J. Influence of Different Chelators (HYNIC, MAG3 and DTPA) on Tumor Cell Accumulation and Mouse Biodistribution of Technetium-99m Labeled to Antisense DNA Eur. J. Nucl. Med. 2000, 27, 1700-1707
52. Cheng, Y.; Prusoff, W. H. Relationship between the Inhibition Constant (K1) and the Concentration of Inhibitor which Causes 50% Inhibition (I50) of an Enzymatic Reaction Biochem. Pharmacol. 1973, 22, 3099-3108